Marco Fornaro
0000-0003-1716-7432
Universita degli Studi Aldo Moro
19 papers found
Refreshing results…
Effectiveness of biological targeted therapies may discriminate seronegative from seropositive rheumatoid arthritis
Prevalence and management of tuberculosis infection in Apulian rheumatologic patients treated with biologics: An observational cohort 10‐year study from the BIOPURE registry
Survival and prognostic factors from a multicentre large cohort of unselected Italian systemic sclerosis patients
Estimated 10-year cardiovascular risk in a large Italian cohort of rheumatoid arthritis patients: Data from the Cardiovascular Obesity and Rheumatic DISease (CORDIS) Study Group
Safety Profile and Low Risk of Disease Relapse After BNT162b2 mRNA SARS-CoV-2 Vaccination in Patients With Rare Rheumatic Diseases
Preliminary Data on Post Market Safety Profiles of COVID 19 Vaccines in Rheumatic Diseases: Assessments on Various Vaccines in Use, Different Rheumatic Disease Subtypes, and Immunosuppressive Therapies: A Two-Centers Study
Predictors of long‐term clinical remission in rheumatoid arthritis
Cardiovascular risk estimation with 5 different algorithms before and after 5 years of bDMARD treatment in Rheumatoid Arthritis
The autoinflammatory side of recurrent pericarditis: enlightening the pathogenesis for a more rational treatment
Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes
Phosphorylated signal transducer and activator of transcription 3 (pSTAT3) is highly expressed in CD14+ circulating cells of scleroderma patients
Response to: ‘Response to: “Influence of changes in cholesterol levels and disease activity on the 10-year cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients” by Fornaro et al’ by Agca et al
Efficacy of baricitinib on refractory skin papulosquamous rash in a patient with systemic lupus erythematosus
Influence of changes in cholesterol levels and disease activity on the 10 years cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients
Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases
Occult HBV infection may negatively impact on drug survival in patients with rheumatoid arthritis on treatment with a first biologic drug. An appraisal from the Biologic Apulian Registry (BIOPURE)
A Bayesian mixed treatment comparison of efficacy of biologics and small molecules in early rheumatoid arthritis
Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment
Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings
Missing publications? Search for publications with a matching author name.